AJR Your Link to CME
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Cine Film
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCann, G. P.
Right arrow Articles by van Rossum, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCann, G. P.
Right arrow Articles by van Rossum, A. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
DOI:10.2214/AJR.05.1259
AJR 2007; 188:349-355
© American Roentgen Ray Society

Original Research

Extent of MRI Delayed Enhancement of Myocardial Mass Is Related to Right Ventricular Dysfunction in Pulmonary Artery Hypertension

Gerry P. McCann1,2, C. T. Gan3, Aernout M. Beek2, Hans W. M. Niessen4, Anton Vonk Noordegraaf3 and Albert C. van Rossum2

1 Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands.
2 Present address: Department of Cardiology, Glenfield Hospital, Groby Rd., Leicester LE3 9QP, United Kingdom.
3 Department of Pulmonology, VU University Medical Center, Amsterdam, The Netherlands.
4 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.

Received August 4, 2005; accepted after revision May 25, 2006.

 
G. P. McCann was supported by a European Society of Cardiology clinical training fellowship, the East Midlands Heart and East Midlands Pacemaker Research Funds.

C. T. Gan was supported by the Netherlands Organisation for Scientific Research, Mosaic grant, project 017.001.154.

Address correspondence to G. P. McCann.


Abstract
Top
 Abstract
Introduction
 Subjects and Methods
 Results
 Discussion
 APPENDIX 1: Histology of...
 References
 
OBJECTIVE. The purpose of our study was to assess the presence and extent of delayed contrast enhancement of ventricular myocardium in pulmonary artery hypertension.

SUBJECTS AND METHODS. Fifteen patients (age, 45.6 ± 13 years; 13 New York Heart Association class III) with pulmonary artery hypertension (11 idiopathic, four systemic sclerosis) were studied. All patients had undergone a comprehensive diagnostic workup, and pulmonary artery hypertension (mean pulmonary artery pressure, 54 ± 16 mm Hg) was confirmed by cardiac catheterization. Cardiac MRI was performed on a 1.5-T scanner to determine ventricular volumes and mass. Delayed contrast enhancement of a mass was seen 10-20 minutes after the IV injection of 0.2 mmol/kg of gadopentetate dimeglumine using an inversion recovery gradient-echo sequence.

RESULTS. All patients showed delayed contrast enhancement at the insertion points of the right ventricular free wall to the interventricular septum (15 inferior, 13 anterior). The mean weight of the delayed contrast-enhanced myocardial mass was 3.1 ± 1.9 g (size range, 0.3-3.9% of the total myocardial mass). The extent of the delayed contrast-enhancing myocardium was inversely related to the right ventricular ejection fraction (r = -0.63, p = 0.001), right ventricular stroke volume (r = -0.67, p = 0.006), and right ventricular end-systolic volume index (r = -0.51, p =0.05) but not to any invasively measured hemodynamic index or N-terminal pro brain natriuretic peptide.

CONCLUSION. Myocardial delayed contrast enhancement occurs frequently in patients with severe symptomatic pulmonary artery hypertension and is inversely related to measures of right ventricular systolic function.

Keywords: cardiac MRI • cardiopulmonary imaging • delayed contrast enhancement • MR contrast agents • MRI • pulmonary artery hypertension • right ventricular function


Introduction
Top
 Abstract
 Introduction
Subjects and Methods
 Results
 Discussion
 APPENDIX 1: Histology of...
 References
 
Pulmonary artery hypertension (PAH) is a disease characterized by increased pulmonary vascular resistance that results in pressure overload on the right ventricle [1]. The right ventricle hypertrophies to normalize wall stress, but other negative adaptions also occur: right ventricular and atrial dilatation, tricuspid regurgitation, and, in severe cases, prominent leftward displacement of the interventricular septum (septal bowing) during early diastole [2]. When these conditions are not treated, progressive right ventricular systolic dysfunction and high mortality occur, predominately resulting from right heart failure but also from sudden cardiac death [1, 3].

Cardiac MRI is the gold standard technique for the assessment of ventricular function and quantification of volumes and mass without geometric assumptions [4]. Right ventricular volumes, mass, and function can be quantified with excellent intra- and interobserver variability [5] and good interstudy reproducibility [6]. The addition of delayed contrast-enhanced cardiac MRI with the inert extracellular contrast agent gadopentetate dimeglumine (Magnevist, Schering) allows in vivo visualization of both infarct-related scars [7] and more diffuse myocardial fibrosis associated with various cardiomyopathies [8-12]. Although there are numerous reports of delayed contrast-enhanced cardiac MRI in conditions affecting the left ventricle, only one study has focused on PAH [13]. Delayed contrast enhancement was seen in the interventricular septum at the right ventricular insertion points in 23 of 25 patients, and the extent of enhancement was related to right ventricular dysfunction and pulmonary hemodynamics [13].

We aimed to assess the presence and extent of delayed contrast enhancement on cardiac MRI in patients with severe PAH. We hypothesized that hyperenhancement would be present in the right ventricle and that the extent of hyperenhancement would correlate with systolic function and hemodynamic indexes of severity.


Subjects and Methods
Top
 Abstract
 Introduction
 Subjects and Methods
Results
 Discussion
 APPENDIX 1: Histology of...
 References
 
Fifteen patients with PAH (11 idiopathic and four associated with systemic sclerosis, the connective tissue disorder) were studied prospectively between May and September 2004. All subjects had undergone a comprehensive diagnostic workup [14], and mean pulmonary artery pressure (PAP) > 25 mm Hg was confirmed by cardiac catheterization in all cases. Patients with other classes of pulmonary hypertension [15] and those with contraindications to cardiac MRI were excluded. One additional patient did not undergo cardiac MRI after informed consent because of claustrophobia. The clinical characteristics of the group are shown in Table 1. Ten patients were undergoing annual follow-up and five were undergoing initial cardiac MRI assessment, which is a routine investigation at our institution for patients with suspected PAH [16]. No changes in medication occurred during testing. Our study conforms with the Declaration of Helsinki, and the protocol was approved in full by our university ethics committee. All patients gave written informed consent before participation.


View this table:
[in this window]
[in a new window]

  		TABLE 1: Patient Characteristics

 

Cardiac MRI
All images were acquired on a 1.5-T clinical scanner (Sonata, Siemens Medical Solutions) with prospective ECG gating during repeated breath-holds of 6-15 seconds, depending on the patient's heart rate.

Cine Imaging
After scout imaging was performed, a steady-state free precession sequence (true fast imaging with steady-state free precession [FISP]) was used to acquire functional images of the heart. Sequence parameters were TR/TE, 3.1/1.6; flip angle, 60°; slice thickness, 5.0 mm; slice spacing, 5.0 mm; 13-15 segments per heart beat, giving a temporal resolution of 40-46 milliseconds. The matrix was 256 x 156, and the field of view was altered (300-400 x 204-352 mm) according to individual patient body size to minimize infolding, giving an in-plane spatial resolution of 1.2-1.6 x 1.3-2.2 mm.

Standard long-axis views—four-chamber, two-chamber, and three-chamber (left ventricular outflow tract)—and right ventricular two- and three-chamber views were obtained. A stack of short-axis slices, planned on the four-chamber view, perpendicular to the interventricular septum and parallel to the plane of the mitral valve, was acquired, with complete coverage from the base to the apex. The stack of short-axis slices allows calculation of left ventricular and right ventricular mass, volume, and ejection fraction without any geometric assumptions [17]. The extent of pericardial effusion was graded according to maximum diameter of fluid seen in any view (0, none; 1, trace; 2, ≤ 10 mm; and 3, > 10 mm) [2]. The left ventricular eccentricity index was calculated at mid ventricular level in the short-axis orientation [2] at end-diastole and during maximal septal displacement during early diastole. Tricuspid regurgitation was graded semiquantitatively by assessing the area of signal void in the right atrium.

Delayed Contrast Enhancement
Delayed contrast-enhanced images were acquired by copying the image position for each of the short-axis slices and long-axis views as for cine images, 10-20 minutes (mean, 14 minutes) after the administration of 0.2 mmol/kg of gadopentetate dimeglumine (Magnevist, Schering) using a 2D inversion recovery fast gradient-echo sequence [18] with triggering on alternate cycles to late diastole ({approx} 100 milliseconds before the next Q wave on the ECG). Sequence parameters were 9.6/4.4; matrix, 256 x 208; flip angle, 25°; slice thickness, 5.0 mm; and slice spacing, 5.0 mm. Meticulous attention was paid to the inversion time to null normal myocardium with typical values of 250-300 milliseconds. Patients with severe tricuspid regurgitation and right ventricular dysfunction tended to require a lower inversion time—approximately 200-220 milliseconds—for optimal nulling. In two patients a single-shot sequence rather than a segmented sequence was used to minimize breathing artifacts [19]. If doubt existed about the presence of hyperenhancement, the phase-encoding direction was switched to enable differentiation from image artifacts.

Because hyperenhancement was not usually seen in the standard long-axis views, a modified two-chamber view planned perpendicularly through the inferior right ventricular insertion point was performed in several patients to show enhancement in a long-axis view. The presence of hyperenhancement was agreed on by two experienced observers. Endocardial and epicardial borders were traced manually, excluding trabeculations and papillary muscles. Hyperenhancement was defined by visual analysis, during which the window setting could be freely adjusted to the personal preference of the observer. Hyperenhanced regions were manually contoured on each short-axis slice, and the total volume of hyperenhancement was calculated by the software package MASS (Medis) and converted to mass by multiplying by 1.05. Delayed contrast-enhanced mass was expressed as a percentage of the total (left ventricular plus right ventricular) myocardial mass. Semiautomatic analysis, by setting a window threshold for signal intensity, was not performed because doing so can lead to large overestimations of hyperenhancement compared with manual contouring [20]. Interobserver agreement for the presence of abnormal delayed contrast enhancement ({kappa}, 0.76) [18] and interobserver (5% ± 18%) and intraobserver (4% ± 7%) variability for quantification of delayed contrast-enhanced mass [20] were excellent for our group of patients.

Cardiac Catheterization
Diagnostic right heart catheterization was performed with a balloon-tipped, flow-directed 7-French Swan-Ganz catheter (131HF7, Baxter Health Care) within 2 days of cardiac MRI measurements in 14 patients. The other patient underwent catheterization at diagnosis but it was not repeated at the time of cardiac MRI, and hemodynamic data are not included for this patient. Right atrial, right ventricular, pulmonary artery, and pulmonary capillary wedge pressures were measured. Blood was sampled with the catheter positioned in the main pulmonary artery. Arterial oxygen saturation was measured from blood sampled from the radial artery. Cardiac output was assessed by the Fick oxygen method, and pulmonary vascular resistance was calculated using the standard formula.

N-Terminal Pro Brain Natriuretic Peptide
The N-terminal pro brain natriuretic peptide (N-BNP) was measured using a commercially available assay within 48 hours of cardiac MRI.

Statistical Analyses
Analyses were performed using the computer software package Minitab, version 11.21 (Minitab). All ventricular volumes and masses were indexed by body surface area. The relationship between the weight of hyperenhanced mass and clinical, hemodynamic, and cardiac MRI variables was assessed using linear regression analysis for continuous and logistic regression analysis for categoric variables. Variables entered into the regression analyses were the clinical variables age, sex, time since diagnosis, N-BNP (log transformed to normalize data), and the 6-minute walking distance; the hemodynamic variables right atrial pressure, mean PAP, right ventricular end-diastolic pressure, pulmonary vascular resistance, and cardiac index; and the cardiac MRI variables right ventricular and left ventricular end-diastolic and end-systolic volumes, masses, and ejection fractions, left ventricular eccentricity index, tricuspid regurgitation grade, and pericardial effusion grade. A formal power calculation was not performed at the time of study planning because to our knowledge there had been no previous publications on delayed contrast enhancement in PAH to guide sample size requirements. Results are expressed as mean ± SD or median, and interquartile range is given where stated. A p value of less than 0.05 was considered statistically significant.


Figure 1
View larger version (176K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1A —Steady-state free precession (true FISP) and delayed contrast-enhanced cardiac MR images in 34-year-old woman with pulmonary artery hypertension. RV = right ventricle, PA = pulmonary artery. See also Figure S1, short-axis image at mid-ventricular level (true FISP), in supplemental data online. End-diastolic true FISP images in four-chamber (A), right ventricle three-chamber (B), and short-axis midventricular level.

 


Figure 2
View larger version (162K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1B —Steady-state free precession (true FISP) and delayed contrast-enhanced cardiac MR images in 34-year-old woman with pulmonary artery hypertension. RV = right ventricle, PA = pulmonary artery. See also Figure S1, short-axis image at mid-ventricular level (true FISP), in supplemental data online. End-diastolic true FISP images in four-chamber (A), right ventricle three-chamber (B), and short-axis midventricular level.

 


Figure 3
View larger version (167K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1C —Steady-state free precession (true FISP) and delayed contrast-enhanced cardiac MR images in 34-year-old woman with pulmonary artery hypertension. RV = right ventricle, PA = pulmonary artery. See also Figure S1, short-axis image at mid-ventricular level (true FISP), in supplemental data online. End-diastolic true FISP images in four-chamber (A), right ventricle three-chamber (B), and short-axis midventricular level.

 


Figure 4
View larger version (158K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 1D —Steady-state free precession (true FISP) and delayed contrast-enhanced cardiac MR images in 34-year-old woman with pulmonary artery hypertension. RV = right ventricle, PA = pulmonary artery. See also Figure S1, short-axis image at mid-ventricular level (true FISP), in supplemental data online. Delayed contrast-enhanced image in identical position to C. Arrows indicate hyperenhanced areas at anterior and inferior insertion points of right ventricle to septum. Note also moderate pericardial effusion.

 

Results
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
Discussion
 APPENDIX 1: Histology of...
 References
 
Ventricular Volumes, Mass, and Function
All subjects completed the imaging protocol, and no adverse reactions to contrast injection occurred. All patients had evidence of right ventricular dilatation (Fig. 1A, 1B, 1C, 1D and Table 2) and tricuspid regurgitation (grade 1, n = 3; grade 2, n = 4; grade 3, n = 2; and grade 4, n = 5). Mean ventricular masses, volumes, and ejection fractions are shown in Table 3. Mean right ventricular volumes and masses were significantly increased and systolic function decreased compared with normal ranges [5]. Mean left ventricular volumes were toward the lower limit of the normal range with a normal ejection fraction [5]. Thirteen of 15 subjects had pericardial effusion (grade 1, n = 4; grade 2, n =4; and grade 3, n = 5). The mean left ventricular eccentricity indexes were 1.4 ± 0.2 in end-diastole and 2.1 ± 0.2 at maximal septal bowing.


View this table:
[in this window]
[in a new window]

  		TABLE 2: Individual Cardiac MRI Right Ventricular Volumes and Delayed Contrast-Enhanced Findings

 

View this table:
[in this window]
[in a new window]

  		TABLE 3: Cardiac MRI: Mean Ventricular Volumes, Mass, and Function

 

Delayed Contrast Enhancement
All patients showed hyperenhancement of ventricular myocardium (mean weight, 3.1 ± 1.9 g; size range, 0.3-3.9% of total myocardial mass) in the interventricular septum. Hyperenhancement occurred almost exclusively at the right ventricular insertion points (15 inferior, 13 anterior) and was more prominent toward the base of the heart (Figs. 1A, 1B, 1C, 1D and 2A, 2B, 2C, 2D). No subendocardial or transmural enhancement and no hyperenhancement were seen in the right ventricular or left ventricular free walls. The extent of hyperenhancement was not correlated with any clinical or hemodynamic variable but was inversely correlated with stroke volume index (r = -0.67, p = 0.006) and right ventricular ejection fraction (r = -0.63, p = 0.01) measured on cardiac MRI. A trend was seen toward significance for the correlation with the right ventricular end-systolic volume index (r = -0.51, p = 0.052).


Figure 5
View larger version (156K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2A —Short-axis and modified two-chamber delayed contrast-enhanced MR images of 42-year-old man with pulmonary artery hypertension. RV = right ventricle, LV = left ventricle. Inversion recovery gradient-echo (turbo FLASH) images show base of right ventricle (A), midventricular level (B), apex of right ventricle in short-axis plane (C), and modified two-chamber view (D). Arrows indicate hyperenhanced areas at anterior and inferior insertion points of right ventricle to interventricular insertion point in pulmonary artery hypertension.

 

Figure 6
View larger version (147K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2B —Short-axis and modified two-chamber delayed contrast-enhanced MR images of 42-year-old man with pulmonary artery hypertension. RV = right ventricle, LV = left ventricle. Inversion recovery gradient-echo (turbo FLASH) images show base of right ventricle (A), midventricular level (B), apex of right ventricle in short-axis plane (C), and modified two-chamber view (D). Arrows indicate hyperenhanced areas at anterior and inferior insertion points of right ventricle to interventricular insertion point in pulmonary artery hypertension.

 

Figure 7
View larger version (157K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2C —Short-axis and modified two-chamber delayed contrast-enhanced MR images of 42-year-old man with pulmonary artery hypertension. RV = right ventricle, LV = left ventricle. Inversion recovery gradient-echo (turbo FLASH) images show base of right ventricle (A), midventricular level (B), apex of right ventricle in short-axis plane (C), and modified two-chamber view (D). Arrows indicate hyperenhanced areas at anterior and inferior insertion points of right ventricle to interventricular insertion point in pulmonary artery hypertension.

 

Figure 8
View larger version (165K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 2D —Short-axis and modified two-chamber delayed contrast-enhanced MR images of 42-year-old man with pulmonary artery hypertension. RV = right ventricle, LV = left ventricle. Inversion recovery gradient-echo (turbo FLASH) images show base of right ventricle (A), midventricular level (B), apex of right ventricle in short-axis plane (C), and modified two-chamber view (D). Arrows indicate hyperenhanced areas at anterior and inferior insertion points of right ventricle to interventricular insertion point in pulmonary artery hypertension.

 

Discussion
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
APPENDIX 1: Histology of...
 References
 
We have shown that delayed enhancement on cardiac MRI occurs frequently at the right ventricular insertion points of the interventricular septum in patients with severe symptomatic PAH and that the extent of hyperenhancement is significantly related to right ventricular systolic dysfunction.

Comparison with Previous Studies
Our findings are similar to the those in the only other report of delayed contrast enhancement in PAH, a study by Blyth et al. [13], in which 23 of 25 patients had hyperenhancement affecting the right ventricular insertion points. The extent of hyperenhancement was similar, as were the correlations with right ventricular volumes and the inverse correlation with the right ventricular ejection fraction [13]. We did not find a significant correlation with invasively measured PAP, probably because of the different populations in the two studies. The subjects in our study tended to have more severe disease, as manifested by greater PAPs, right ventricular volumes, reduced systolic function, and longer duration of illness. In the study by Blyth et al., patients were not receiving any specific treatment for pulmonary hypertension, whereas most of our patients were being reassessed for response to treatments that reduce PAP. This fact may explain why delayed contrast enhancement did not correlate with invasive hemodynamics in our study.

Delayed contrast enhancement of the septal right ventricular insertion point has also been reported in congenital heart disease with right ventricle overload [21, 22]. In transposition of the great arteries, in which right ventricular pressures may be similar to those in severe PAH, the extent of hyperenhancement also correlates inversely with right ventricular ejection fraction [21].

Cause of Delayed Contrast Enhancement in PAH
Delayed contrast enhancement has been characterized best in relation to ischemic heart disease. The typical pattern is of transmural or subendocardial enhancement following the territory supplied by one or more coronary arteries [7, 18, 23]. In this situation, hyperenhancement represents a collagenous scar formation [7]. The extent of delayed enhancement on cardiac MRI has also correlated significantly with myocardial collagen, but not with myocyte disarray, in a single patient with hypertrophic obstructive cardiomyopathy who underwent heart transplantation [24]. In other forms of cardiomyopathy, late enhancement is also likely to represent interstitial fibrosis [9, 11]. Enhancement at the right ventricular insertion points has been seen, particularly in patients with hypertrophic cardiomyopathy [10, 25], and may reflect focal fibrosis [26]. Myocardial disarray is frequently seen at the right ventricular junctions, even in healthy subjects [27], but disarray was not related to enhancement in an individual patient with hypertrophic obstructive cardiomyopathy [24].

Histologic studies of PAH have focused on changes in the pulmonary vasculature [28]. We, like other authors [13], failed to identify any reports of histologic changes in the right ventricular myocardium in patients with PAH despite the importance of right ventricular function to prognosis [3]. Given that all the patients in our study and all but two (with mild disease and normal right ventricular function) of 25 in a previous report [13] showed delayed contrast enhancement at the right ventricular insertion points, we think that histologic results obtained in two patients with PAH who died and underwent postmortem autopsy, but who did not undergo cardiac MRI during the study period, are likely to be representative of PAH patients in general. In these two patients, fibrosis was present at the right ventricular insertion points (Appendix 1 and Fig. 3A, 3B, 3C) suggesting that this is the causal mechanism of delayed contrast enhancement in our study. However, we also saw evidence of interstitial space expansion, which may increase the volume of distribution of gadopentetate dimeglumine and contribute to hyperenhancement in these areas. Indeed, inflammation is an early response to pressure overload leading to interstitial fibrosis [29] and is also associated with delayed contrast enhancement in acute myocarditis [30]. The small increase in fat, seen at a distance from the perivascular regions, may also contribute to hyperenhancement in these areas because fat also has a high signal intensity on the inversion recovery gradient-echo sequence used for delayed contrast enhancement.


Figure 9
View larger version (177K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3A —Specimens from interventricular septum of 23-year-old woman show histology of interventricular septum and anterior right ventricular insertion point in pulmonary artery hypertension. Photomicrographs show anterior insertion points (A and B) and mid septum (C). Note fat (asterisk, B and C), extracellular expansion and edema (pound sign, A), and fibrosis (triangle, A and B), which appears purple. (A and C, H and E, x50; B, elasticavan Gieson stain, x100)

 

Figure 10
View larger version (183K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3B —Specimens from interventricular septum of 23-year-old woman show histology of interventricular septum and anterior right ventricular insertion point in pulmonary artery hypertension. Photomicrographs show anterior insertion points (A and B) and mid septum (C). Note fat (asterisk, B and C), extracellular expansion and edema (pound sign, A), and fibrosis (triangle, A and B), which appears purple. (A and C, H and E, x50; B, elasticavan Gieson stain, x100)

 

Figure 11
View larger version (189K):
[in this window]
[in a new window]
[as a PowerPoint slide]
  		Fig. 3C —Specimens from interventricular septum of 23-year-old woman show histology of interventricular septum and anterior right ventricular insertion point in pulmonary artery hypertension. Photomicrographs show anterior insertion points (A and B) and mid septum (C). Note fat (asterisk, B and C), extracellular expansion and edema (pound sign, A), and fibrosis (triangle, A and B), which appears purple. (A and C, H and E, x50; B, elasticavan Gieson stain, x100)

 
Location of Delayed Contrast Enhancement
The most surprising aspect of our study is that no delayed contrast enhancement was seen in the right ventricular free wall, even though most of the patients had evidence of severe systolic dysfunction. Contrast enhancement in thin-walled ventricles, such as in arrhythmogenic right ventricular dysplasia, may be difficult to detect because of partial volume effects, but the patients in our study had marked right ventricular hypertrophy, and we did not have any difficulty nulling the right ventricular myocardium (Figs. 1A, 1B, 1C, 1D and 2A, 2B, 2C, 2D). It is unlikely that diffuse homogeneous fibrosis affects the right ventricle because the inversion time to null the right ventricle would have been different from that of the left ventricle, and we did not see any fibrosis in the interventricular septum on histology other than at the right ventricular insertion points.

These findings suggest that the insertion points are particularly prone to developing fibrosis. These junctional areas have considerable forces acting on them—the circumferential strain of left ventricular myocardial shortening and right ventricular longitudinal shortening—which may explain why myocardial disarray and some fibrosis not extending into the mid myocardium may be observed in healthy individuals [27]. In PAH, the force generation required for right ventricular systolic emptying is greatly increased and there is the added abnormal interventricular septal motion, which may create further shear stress at the interventricular septal insertion points. However, the pattern of delayed contrast enhancement is specific neither to the underlying cause [13] nor to PAH [10, 25].

Significance of Delayed Contrast Enhancement
The extent of delayed contrast enhancement in this study was moderately correlated with cardiac MRI parameters of right ventricular dysfunction. Right ventricular systolic dysfunction is closely related to right heart failure, the commonest cause of death in PAH [1, 31], but right ventricular ejection fraction is difficult to measure with echocardiography, and there is a lack of outcome studies with cardiac MRI-measured ejection fraction. No significant correlation was seen with any other hemodynamic or clinical variable that has been shown to predict outcome in PAH [3, 15]. Therefore, the significance of contrast enhancement is unclear and remains to be elucidated in a longitudinal study of PAH. Delayed contrast enhancement in hypertrophic cardiomyopathy correlates with risk factors for sudden death [10] and, in transposition of the great arteries, with clinical events, including syncope and nonsustained ventricular tachycardia [21]. One may speculate that the focal nature of the delayed contrast enhancement in PAH, which probably represents fibrosis, may act as a trigger for potentially fatal ventricular tachyarrhythmias contributing to the risk of sudden cardiac death.

Study Limitations
The patients in this study were highly selected, and therefore our results may not be applicable to patients with less severe PAH. The cause and significance of delayed contrast enhancement in PAH need to be determined in future studies. Because this is a cross-sectional study, we are uncertain whether delayed contrast enhancement precedes right ventricular dysfunction, and we cannot say that they are causally related. As in other conditions, the extent of delayed contrast enhancement may vary with time [32, 33], although because the PAP remains elevated we assume the stimuli causing hyperenhancement will also remain, making regression of hyperenhancement less likely. The severity of tricuspid incompetence was assessed semiquantitatively on steady-state free precession imaging and may be underestimated in comparison with fast gradient-echo imaging.

Conclusion
Delayed enhancement on cardiac MRI occurs frequently in patients with severe symptomatic PAH and is inversely related to measures of right ventricular systolic function. The significance of hyperenhancement in this population needs to be determined in a longitudinal study.


APPENDIX 1: Histology of Pulmonary Artery Hypertension
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 APPENDIX 1: Histology of...
References
 
Two women with pulmonary artery hypertension (PAH) who had not taken part in the current cardiac MRI protocol died during the study period, and autopsy was performed. Patient A was 23 years old, had severe familial PAH (mean pulmonary artery pressure [PAP], 90 mm Hg in April 2003) associated with the BMPR2 mutation and died from pulmonary hemorrhage. Patient B was 75 years old, had moderately severe idiopathic PAH (mean PAP, 46 mm Hg in September 2004) and died from multiorgan failure secondary to a lower respiratory tract infection. After the hearts were inspected macroscopically, the anterior and inferior insertion points of the right ventricular to interventricular septum and the mid septum were sampled at basal, mid, and apical levels. Tissue was prepared with H and E and elastica-van Gieson stains to identify areas of myocardial fibrosis.

Both patients showed similar histologic changes. The results for patient A are shown in Figure 3A, 3B, 3C. The mid interventricular septum had an essentially normal appearance with closely packed cardiomyocytes and minimal fatty deposition in the perivascular regions (Fig. 3C). At the insertion points of the right ventricle to the interventricular septum (Figs. 3A and 3B) was seen cardiomyocyte disarray with marked expansion of extracellular spaces adjacent to areas of interstitial or replacement fibrosis and increased fat deposition, beyond the perivascular regions.


References
Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 APPENDIX 1: Histology of...
 References
 

  1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111 -117[Free Full Text]
  2. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39:1214 -1219[Abstract/Free Full Text]
  3. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126 [1 suppl]:78S -92S[CrossRef][Medline]
  4. Pennell DJ, Sechtem UP, Higgins CB, et al. Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report. Eur Heart J 2004;25 : 1940-1965[Free Full Text]
  5. Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging 2003;17 : 323-329[CrossRef][Medline]
  6. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J2004; 147:218 -223[CrossRef][Medline]
  7. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100 : 1992-2002[Abstract/Free Full Text]
  8. Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol2003; 41:1568 -1572[Free Full Text]
  9. McCrohon JA, Moon JCC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108 : 54-59[Abstract/Free Full Text]
  10. Moon JCC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41:1561 -1567[Abstract/Free Full Text]
  11. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24:2151 -2155[Abstract/Free Full Text]
  12. van Dockum WG, ten Cate FJ, ten Berg JM, et al. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol2004; 43:27 -34[Abstract/Free Full Text]
  13. Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J 2005;26 : 1993-1999[Abstract/Free Full Text]
  14. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126 [1 suppl]:14S -34S[CrossRef][Medline]
  15. Task FM, Galie N, Torbicki A, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25 : 2243-2278[Free Full Text]
  16. Marcus JT, Vonk Noordegraaf A, Roeleveld RJ, et al. Impaired left ventricular filling due to right ventricular pressure overload in primary pulmonary hypertension: noninvasive monitoring using MRI. Chest 2001; 119:1761 -1765[CrossRef][Medline]
  17. Grothues F, Smith GC, Moon JCC, et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol2002; 90:29 -34[CrossRef][Medline]
  18. Beek AM, Kuhl HP, Bondarenko O, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol 2003; 42:895 -901[Abstract/Free Full Text]
  19. Wei L, Li BSY, Polzin JA, Mai VM, Prasad PV, Edelman RR. Myocardial delayed enhancement imaging using inversion recovery single-shot steady-state free precession: initial experience. J Magn Reson Imaging 2004; 20:327 -330[CrossRef][Medline]
  20. Bondarenko O, Beek AM, Hofman MBM, et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J Cardiovasc Magn Reson 2005;7 : 481-485[Medline]
  21. Babu-Narayan SV, Goktekin O, Moon JC, et al. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation 2005;111 : 2091-2098[Abstract/Free Full Text]
  22. Babu-Narayan SV, Kilner PJ, Li W, et al. Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation 2006;113 : 405-413[Abstract/Free Full Text]
  23. Kim RJ, Wu E, Rafael A, et al. The use of contrastenhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445 -1453[Abstract/Free Full Text]
  24. Moon JCC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43 : 2260-2264[Abstract/Free Full Text]
  25. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;40 : 2156-2164[Abstract/Free Full Text]
  26. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000;84 : 476-482[Abstract/Free Full Text]
  27. Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 1992;70 : 1333-1340[CrossRef][Medline]
  28. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43[12 supplement S]: 25S-32S[Abstract/Free Full Text]
  29. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13 : 1637-1652[Abstract]
  30. Mahrholdt H, Wagner A, Parker M, et al. Relationship of contractile function to transmural extent of infarction in patients with chronic coronary artery disease. J Am Coll Cardiol 2003;42 : 505-512[Abstract/Free Full Text]
  31. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005;16 : 13-18[CrossRef][Medline]
  32. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005; 26:549 -557[Abstract/Free Full Text]
  33. Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison with histology and molecular pathology. Circulation2004; 109:1250 -1258[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Figures Only
Right arrow Full Text (PDF)
Right arrow Cine Film
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCann, G. P.
Right arrow Articles by van Rossum, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCann, G. P.
Right arrow Articles by van Rossum, A. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS